Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126,468,243
-
Total 13F shares
-
51,164,991
-
Share change
-
+605,221
-
Total reported value
-
$306,457,439
-
Put/Call ratio
-
13%
-
Price per share
-
$5.99
-
Number of holders
-
102
-
Value change
-
+$3,407,218
-
Number of buys
-
52
-
Number of sells
-
46
Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q2 2019
As of 30 Jun 2019,
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) was held by
102 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,164,991 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Consonance Capital Management LP, Palo Alto Investors LP, BlackRock Inc., ORBIMED ADVISORS LLC, VANGUARD GROUP INC, Point72 Asset Management, L.P., Candriam Luxembourg S.C.A., EMERALD ADVISERS, LLC, and EMERALD MUTUAL FUND ADVISERS TRUST.
This page lists
102
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.